Illumina, Inc. (NASDAQ:ILMN) has received an average recommendation of “Hold” from the twenty-six research firms that are presently covering the stock. Three investment analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation, ten have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $158.01.
Several research analysts recently weighed in on ILMN shares. CL King raised Illumina from a “neutral” rating to a “buy” rating in a research note on Friday, January 6th. Vetr raised Illumina from a “buy” rating to a “strong-buy” rating and set a $148.34 target price for the company in a report on Tuesday, January 3rd. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $187.00 target price (up from $170.00) on shares of Illumina in a report on Friday, April 14th. Evercore ISI raised Illumina from a “hold” rating to a “buy” rating and set a $190.00 target price for the company in a report on Monday, February 27th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $150.00 target price on shares of Illumina in a report on Wednesday, January 11th.
In other news, Director Daniel Bradbury sold 600 shares of Illumina stock in a transaction that occurred on Friday, April 7th. The stock was sold at an average price of $172.79, for a total transaction of $103,674.00. Following the sale, the director now owns 17,065 shares of the company’s stock, valued at approximately $2,948,661.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director A Blaine Bowman sold 3,000 shares of Illumina stock in a transaction that occurred on Wednesday, April 12th. The stock was sold at an average price of $172.72, for a total value of $518,160.00. Following the sale, the director now directly owns 18,704 shares in the company, valued at approximately $3,230,554.88. The disclosure for this sale can be found here. Insiders sold a total of 12,476 shares of company stock worth $2,078,440 in the last ninety days. Insiders own 1.60% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. Global X Management Co. LLC increased its position in Illumina by 1,400.0% in the third quarter. Global X Management Co. LLC now owns 600 shares of the life sciences company’s stock valued at $109,000 after buying an additional 560 shares during the period. Gemmer Asset Management LLC increased its position in Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock valued at $117,000 after buying an additional 37 shares during the period. B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund bought a new position in Illumina during the third quarter valued at approximately $171,000. Stanford Investment Group Inc. increased its position in Illumina by 5.7% in the fourth quarter. Stanford Investment Group Inc. now owns 1,400 shares of the life sciences company’s stock valued at $179,000 after buying an additional 75 shares during the period. Finally, RMB Capital Management LLC bought a new position in Illumina during the fourth quarter valued at approximately $219,000. 92.79% of the stock is currently owned by institutional investors.
Illumina (NASDAQ:ILMN) traded down 1.06% during mid-day trading on Friday, hitting $175.29. 1,303,066 shares of the stock traded hands. The stock has a market cap of $25.64 billion, a PE ratio of 57.10 and a beta of 0.79. Illumina has a 12-month low of $119.37 and a 12-month high of $186.88. The company has a 50 day moving average of $169.25 and a 200-day moving average of $152.32.
Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, January 31st. The life sciences company reported $0.85 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.82 by $0.03. Illumina had a return on equity of 22.89% and a net margin of 19.31%. The business earned $619 million during the quarter, compared to analysts’ expectations of $612.50 million. During the same quarter last year, the business posted $0.81 earnings per share. The company’s quarterly revenue was up 4.6% on a year-over-year basis. Equities research analysts forecast that Illumina will post $3.64 earnings per share for the current year.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.